<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">supported by timely therapeutic intervention. Hematopoietic stem cell transplantation reverses most of the GATA2-deficient clinical phenotypes with good long-term outcomes</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MSc</roleName><forename type="first">Sara</forename><surname>Ciullini Mannurita</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Marina</forename><surname>Vignoli</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, PhD</roleName><forename type="first">Gloria</forename><surname>Colarusso</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Fabio</forename><surname>Tucci</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">the Hematology-Oncology Department</orgName>
								<orgName type="institution">Anna Meyer Children&apos;s Hos-pital,&apos;&apos; Florence</orgName>
								<address>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Marinella</forename><surname>Veltroni</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">the Hematology-Oncology Department</orgName>
								<orgName type="institution">Anna Meyer Children&apos;s Hos-pital,&apos;&apos; Florence</orgName>
								<address>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Stefano</forename><surname>Frenos</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">the Hematology-Oncology Department</orgName>
								<orgName type="institution">Anna Meyer Children&apos;s Hos-pital,&apos;&apos; Florence</orgName>
								<address>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Veronica</forename><surname>Tintori</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">the Hematology-Oncology Department</orgName>
								<orgName type="institution">Anna Meyer Children&apos;s Hos-pital,&apos;&apos; Florence</orgName>
								<address>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maurizio</forename><surname>Aric</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">the Hematology-Oncology Department</orgName>
								<orgName type="institution">Anna Meyer Children&apos;s Hos-pital,&apos;&apos; Florence</orgName>
								<address>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Venetia</forename><surname>Bigley</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Cellular Medicine</orgName>
								<orgName type="institution">Newcastle University</orgName>
								<address>
									<settlement>Newcastle upon Tyne</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, PhD</roleName><forename type="first">Matthew</forename><surname>Collin</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Cellular Medicine</orgName>
								<orgName type="institution">Newcastle University</orgName>
								<address>
									<settlement>Newcastle upon Tyne</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Claudio</forename><surname>Favre</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">the Hematology-Oncology Department</orgName>
								<orgName type="institution">Anna Meyer Children&apos;s Hos-pital,&apos;&apos; Florence</orgName>
								<address>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Eleonora</forename><surname>Gambineri</surname></persName>
							<email>eleonora.gambineri@unifi.it.</email>
							<affiliation key="aff1">
								<orgName type="department">the Hematology-Oncology Department</orgName>
								<orgName type="institution">Anna Meyer Children&apos;s Hos-pital,&apos;&apos; Florence</orgName>
								<address>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Department of &apos;&apos;NEUROFARBA,&apos;&apos; Section of Child&apos;s Health</orgName>
								<orgName type="institution">University of Florence</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">supported by timely therapeutic intervention. Hematopoietic stem cell transplantation reverses most of the GATA2-deficient clinical phenotypes with good long-term outcomes</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">6676985E75D531F4DB2437DE0FDFBC13</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:40+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>We thank the patient and his family for their support and cooperation.</s><s>We greatly appreciate the collaboration with the Genetic Department of AOU Meyer for the chimerism and FISH analysis.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria</head><p><s>To the Editor:</s></p><p><s>Cholinergic urticaria (CholU) is a frequent skin disorder characterized by itchy wheals induced by physical exercise and passive warming.</s><s>Although CholU affects up to 20% of young adults, 1 its etiopathogenesis is still not fully understood. <ref type="bibr">2</ref></s><s>Secondgeneration antihistamines (sgAHs) are the first-line therapy in patients with CholU, but many patients do not respond to standard sgAH doses. <ref type="bibr">3,</ref><ref type="bibr">4</ref></s><s>In these patients the European Academy of Allergy and Clinical Immunology/GA 2 LEN/EDF/World Allergy Organization urticaria guidelines recommend sgAH updosing, <ref type="bibr">5</ref> for which there is very little evidence. <ref type="bibr">6,</ref><ref type="bibr">7</ref></s><s>One of the reasons for this is that CholU used to be difficult to study because of the lack of validated outcome measures.</s><s>To address this gap, we developed a CholU severity index (CholUSI) <ref type="bibr">8</ref> and a CholU activity score (CholUAS7; see the Methods section in this article's Online Repository at www.jacionline.org).</s><s>Very recently, we also developed and published a standardized specific pulsecontrolled ergometry (PCE) protocol for the diagnosis of CholU, as well as to objectively evaluate disease activity. <ref type="bibr">8</ref></s><s>ere we assessed the efficacy of sgAH updosing in patients with CholU refractory to standard treatment by using the CholUSI, CholUAS7, and PCE, as well as a skin health-related quality-of-life instrument, the Dermatology Life Quality Index (DLQI).</s></p><p><s>Patients with CholU who had been treated with at least 1 sgAH at the licensed dose without achieving sufficient symptom control were enrolled (for study design, see Fig E1 in this article's Online Repository at www.jacionline.org).</s><s>Their severity of disease was assessed at baseline by using the CholUSI and physician global assessment (PGA).</s><s>Patients documented their symptoms for 7 days without taking antihistamines, completed the DLQI, and performed the PCE provocation test (30-minute bicycle challenge with a controlled increase of 3 pulse beats/min). <ref type="bibr">8</ref></s><s>Patients were subsequently treated with an sgAH at 4-fold the licensed dose for 7 to 28 days (mean treatment duration 6 SD, 9.8 6 4.9 days) and reassessed by using the PCE and DLQI at the end of the treatment phase.</s><s>Throughout the study, patients documented their CholU signs and symptoms, as well as exposure to eliciting triggers, in a daily diary.</s><s>The 7-day CholUAS7 score was calculated with these data and chosen to determine best changes in disease activity in response to treatment.</s><s>For a detailed description of the study, applied methods and score descriptions, see the Methods section and Tables E1-E3 in this article's Online Repository.</s><s>In total, 32 patients with CholU were screened for this study, and 28 of them (20 female patients; mean age, 34.0 years; mean duration of disease, 7.6 years; mean duration of wheal episodes, 1.5 hours) were included.</s><s>Detailed clinical characteristics of the patients are listed in Table <ref type="table" target="#tab_4">E4</ref> in this article's Online Repository at www.jacionline.org.</s></p><p><s>Analyzing the diary-recorded disease activity, sgAH treatment at 4-fold the standard dose overall significantly (P 5 .01)</s><s>reduced the CholUAS7 disease activity score by 241% (CholUAS7 components: Wheal7, 238% [P 5 .01];</s><s>Pruritus7, 241% [P 5 .002];</s><s>and Elic-itor7, 23.5% [P 5 not significant]; Table <ref type="table" target="#tab_0">I</ref>) compared with baseline.</s></p><p><s>UAS score-based PCE provocation test results at 4-fold standard dose sgAH treatment also improved, although not significantly (UASprovo, 213% [P 5.08]; Table <ref type="table" target="#tab_0">I</ref>).</s><s>Interestingly, PCE threshold levels (ie, time to wheal onset, time to sweating onset, and change in core body temperature before wheal onset were not reduced by high-dose sgAH treatment; Table <ref type="table" target="#tab_0">I</ref>).</s></p><p><s>Health-related quality of life, as determined by using the DLQI, showed an improvement of 21% during high-dose sgAH treatment compared with baseline values (P 5 .09,</s><s>Table <ref type="table" target="#tab_0">I</ref>).</s></p><p><s>In the detailed responder analysis only 11 (39%) of 28 patients treated with high-dose sgAHs reported an improvement in the CholUAS7 disease activity score of 50% or greater (CholWheal7, 43% of patients; CholPruritus7, 46% of patients; Fig <ref type="figure" target="#fig_0">1, A</ref>). Complete response, as defined by CholUAS7 improvement of greater than 90%, was achieved in only 1 patient (Fig <ref type="figure" target="#fig_0">1, A</ref>).</s><s>In the PCE responder analysis only 2 (7%) of 28 patients showed an improvement in their UASprovo scores of 50% or greater (Whealprovo, 4%; Itchprovo, 36%; Fig <ref type="figure" target="#fig_0">1, B</ref>).</s><s>With PCE, none of the patients had a greater than 90% reduction in UASprovo score.</s></p><p><s>In the responder analysis less than half of all patients had a substantial improvement in the DLQI score during high-dose sgAH treatment (Fig 1 <ref type="figure">, C</ref>). Patients whose CholUAS7   diary-based disease activity score improved typically also had health-related quality-of-life DLQI score improvement (r s 5 0.55, P 5 .002).</s><s>Interestingly, the DLQI score improved significantly in patients with CholU with mild disease (baseline PGA, 1; mean reduction in DLQI score, 4.3 points; n 5 7) but not in severely affected patients (baseline PGA, 3; mean reduction in DLQI score, 0.4 points; n 5 14; P &lt; .05).</s><s>Supplemental results of the study are provided in the Results section in this article's Online Repository at www.jacionline.org.</s></p><p><s>In this study, for the first time, we report that patients with difficult-to-treat CholU can benefit from high-dose sgAHs, as recommended by the current guidelines. <ref type="bibr">5</ref></s><s>The efficacy of sgAH updosing was significant but overall moderate, with a reduction in disease activity of about 40%.</s><s>Two older studies using cetirizine updosing 6,7 also reported significant symptom reduction in patients with CholU, both with much smaller patient groups.</s><s>The first of these studies did not provide information on effect size. <ref type="bibr">6,</ref><ref type="bibr">7</ref></s><s>The second study, with 11 patients with CholU, found that disease activity was reduced by 80%. <ref type="bibr">6,</ref><ref type="bibr">7</ref></s><s>This difference in efficacy is most likely explained by differences in the patient populations studied and the outcome measures used.</s></p><p><s>Importantly, less than half of our patients with CholU had a clinically meaningful reduced disease activity (ie, &gt;50% reduction) in response to high-dose sgAH treatment.</s><s>Improvement as assessed by diary-derived data (CholUAS7 score) correlated with improvement in the DLQI score.</s><s>Furthermore, in a distinct subgroup of patients whose PCE provocation results improved (at maximum elicitation level) regarding the UASprovo, this improvement also correlated with improvements in DLQI scores.</s><s>These results indicate that a distinct subgroup of patients benefits from sgAH updosing.</s><s>The fact that only 1 of 28 patients became virtually symptom free on high-dose sgAH treatment confirms that CholU is a hard-to-treat form of chronic urticaria and that additional and more effective treatment options are needed for patients with this condition.</s></p><p><s>Surprisingly, PCE provocation testing did not detect changes in disease activity in response to high-dose sgAH treatment.</s><s>This is different from other forms of inducible urticaria (eg, cold urticaria), in which responses to antihistamine treatment can be assessed by measuring changes in trigger thresholds (eg, critical temperature thresholds). <ref type="bibr" target="#b17">9</ref></s><s>In contrast to sgAHs, treatment with an anticholinergic drug was found in a previous case to change PCE trigger thresholds (ie, to increase the time to onset of PCE-induced wheals). <ref type="bibr" target="#b18">10</ref></s><s>It might be that sgAHs can protect from CholU symptoms induced by mild-to-moderate elicitors (daily life situation) but not those induced by strong elicitors (PCE).</s></p><p><s>Although our study was not performed or powered to compare different sgAHs, our analysis did not find gross differences in the efficacy of different sgAHs (see Table <ref type="table" target="#tab_5">E5</ref> in this article's Online Repository at www.jacionline.</s><s>org).</s><s>However, this does not mean that such differences do not exist or could not be detected in future studies with greater patient numbers.</s></p><p><s>In conclusion, this study addresses a common situation in the treatment of patients with CholU (ie, need for sgAH updosing).</s><s>The use of multiple methods to analyze the outcome of updosing, including the use of diary-based activity scores (patient-centered methods), supports our findings and makes them relevant for routine patient management.</s><s>The limitations of our study are that it was not placebo controlled and not blind and that the study design did not allow for direct comparisons of the effects of standard and high-dose sgAHs or of different types of sgAHs used in the same patients.</s><s>Overall, sgAH updosing in patients with CholU refractory to standard doses substantially improves disease activity but only in less than half of all patients.</s><s>Accordingly, further randomized double-blind, placebo-controlled trials in stratified patients receiving single sgAHs and more or new effective treatment options are needed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Successful hematopoietic stem cell transplantation for myelofibrosis in an adult with warts-hypogammaglobulinemiaimmunodeficiency-myelokathexis syndrome</head><p><s>To the Editor:</s></p><p><s>Warts-hypogammaglobulinemia-immunodeficiency-myelokathexis (WHIM) syndrome is a rare autosomal-dominant disorder characterized by severe neutropenia, B-cell lymphopenia,</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS Patients</head><p><s>Patients with CholU were recruited from the urticaria specialty clinic of the Department of Dermatology and Allergy, Charit e-Universit€ atsmedizin Berlin.</s><s>This specialized outpatient clinic serves patients referred by office-based dermatologists or allergologists (tertiary referral center).</s><s>All patients had been treated before the study with at least 1 sgAH at the licensed dose without achieving sufficient symptom control, and none had taken systemic corticosteroids for at least 2 weeks or applied topical antihistamines, corticosteroids, or mast cell stabilizers for 1 week before study enrollment.</s><s>Patients younger than 18 years, pregnant or breast-feeding women, patients with known iodine allergy, patients with severe skin diseases who might not tolerate skin sensors, and patients who participated in other clinical trials were excluded from the study.</s><s>Patients' characteristics and baseline data are presented in Table <ref type="table" target="#tab_4">E4</ref>.</s></p><p><s>A total of 32 patients were enrolled in the study.</s><s>One patient withdrew his consent during the study, and 3 patients did not adhere to the study protocol.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>The study design is depicted in Fig E1 <ref type="figure">.</ref></s><s>After enrollment at visit 0, patients documented their symptoms in a daily diary for 7 days without taking antihistamines, and they completed the DLQI at the last of these 7 days.</s><s>On day 7 (visit 1), we performed PCE provocation testing and determined the severity of disease with the CholUSI, as described previously, E1 and PGA.</s><s>Patients were subsequently treated with an sgAH at 4-fold the licensed dose for 7 to 28 days (mean treatment duration 6 SD, 9.8 6 4.9 days) and reassessed by using PCE and the DLQI at visit 2 at the end of the treatment phase.</s><s>For 7 days before visit 2, patients again documented their symptoms in a daily diary.</s></p><p><s>The study was approved by the Ethics Committee of the Charit e-Universit€ atsmedizin Berlin (EA4/124/10), which is registered in the German Clinical Trials Registry (DRKS-ID: DRKS00004277), and conducted according to the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice Guidelines, national laws, and regulations, as well as the Standard Operating Procedures of the Allergie-Centrum-Charit e.</s><s>All participants provided signed informed consent before entering the study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outcome measures</head><p><s>Disease severity.</s><s>CholU severity was assessed at baseline by using the CholUSI and PGA.</s><s>The CholUSI E1 is a sum score of (1) the frequency of CholU symptoms (less than once a month 5 0; once a month 5 1; more than once a month 5 2; once a week 5 3; more than once a week 5 4; daily 5 5; and more than once daily 5 6 points), (2) eliciting factors (1 point for each: physical exercise, hot bath, hot shower, emotional stress, hot food, sauna, and other), (3) duration of skin lesions (&lt;5 min 5 0; 5-10 minutes 5 1; 10-20 minutes 5 2; 20-30 minutes 5 3; 30-60 minutes 5 4; and &gt;1 hour 5 5 points), and (4) itch (none 5 0; mild 5 1; moderate 5 2; and severe 5 3 points).</s><s>Accordingly, the CholUSI score ranges from 0 to 21 points (very mild 5 1 to 4 points; mild 5 5 to 9 points; moderate 5 10 to 15 points; and severe 5 greater than 16 points).</s><s>The PGA is a subjective measure of the patient's overall CholU severity, ranging from 0 to 3 points (none 5 0; mild 5 1; moderate 5 2; and severe 5 3).</s></p><p><s>Patient diary.</s><s>In the diary patients documented their CholU signs and symptoms, as well as trigger factors, during the baseline and treatment phases.</s><s>Specifically, patients recorded their itch intensity (Itchday: none 5 0; mild 5 1; moderate 5 2; and severe 5 3 points) and wheal intensity (Whealday: none 5 0; mild 5 1; moderate 5 2; and severe 5 3 points) once a day to assess disease activity.</s><s>Because patients with CholU usually exhibit pinpoint-sized wheals that are difficult to count, patients globally rated their intensity instead of counting wheal numbers, as done in patients with chronic spontaneous urticaria.</s><s><ref type="bibr">E2</ref> Furthermore, the patients were advised to continue their daily routine and avoid extreme trigger situations and were to document elicitors in their daily dairies once daily.</s><s>Patients documented exposure to elicitors of symptom development, such as physical exercise, and the intensity of the elicitor to which they were exposed (intensity of Elicitorday: no exposure to elicitors 5 4; exposure to mild elicitor 5 3; exposure to moderate elicitor 5 2; and exposure to strong elicitor 5 1 point).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quality of life.</head><p><s>Health-related quality-of-life impairment was assessed the day before the PCE, both in the baseline and treatment phases, by using the DLQI, <ref type="bibr">E3</ref> a patient-reported outcome instrument specifically designed for dermatologic disorders.</s><s>The DLQI has a recall period of 7 days and consists of 10 questions, with a minimum and maximum possible score of 0 and 30, respectively.</s><s>The commonly used interpretation of DLQI scores is as follows: no impairment 5 0 to 1 points; mild impairment 5 2 to 5 points; moderate impairment 5 6 to 10 points; very large impairment 5 11 to 20 points; and extremely large impairment 5 21 to 30 points.</s><s>PCE provocation test.</s><s>PCE provocation testing was performed, as previously described, to (1) verify the diagnosis of CholU (at visit 1) and ( <ref type="formula">2</ref>) assess post-PCE wheal intensity and disease activity, as well as trigger thresholds (at visits 1 and 2).</s><s><ref type="bibr">E1</ref> In brief, patients performed a 30-minute bicycle ride in a pulse-controlled manner; that is, patients were instructed to speed up or slow down their pedaling speed for 30 minutes to achieve an increase in pulse rate of 3 beats/min to a final maximum increase of 90 beats/min above the starting level.</s><s>PCE provocation test-induced urticaria activity was assessed by using the UASprovo score (ie, the sum score of the highest itch intensity [Pruritusprovo: none 5 0, mild 5 1, moderate 5 2, and severe 5 3 points] and the highest wheal intensity [Whealprovo: none 5 0, mild 5 1, moderate 5 2, and severe 5 3 points]) that occurred during PCE and up to 15 minutes thereafter, with a minimum and maximum possible score of 0 and 6 points, respectively.</s><s>In addition, time to sweating using the Minor sweat test (iodine starch reaction) <ref type="bibr">E4</ref> and individual CholU trigger thresholds (ie, time to first wheal) was assessed and documented during and up to 15 minutes after PCE testing.</s></p><p><s>Core body temperature.</s><s>To assess core body temperature, 20 minutes of acclimatization time was allowed before PCE, during which patients were fitted with a Double Sensor device attached to the forehead (Double Sensor T DS ; Dr€ agerwerk AG, L€ ubeck, Germany) E5-E7 with 2-sided adhesive ring tape.</s><s>A chest-strap pulse monitor (Polar Electro GmbH, B€ uttelborn, Germany) was used to monitor pulse rate.</s><s>All sensors were operated by Health Lab System (Koralewski, Hamb€ uhren, Germany).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Calculation of diary scores</head><p><s>To determine which diary score is best suited to assess changes of disease activity in response to treatment, we calculated and compared different scores (Table <ref type="table" target="#tab_1">E1</ref>).</s></p><p><s>The 3 composite diary scores (UAS7, CholUAS7, and aCholUAS7) at baseline were correlated with provocation-based assessments of disease activity (UASprovo, Whealprovo, and Pruritusprovo), CholU trigger thresholds (ie, time to wheal onset in PCE), and health-related quality of life (DLQI) as anchors (Table <ref type="table" target="#tab_2">E2</ref>).</s></p><p><s>This identified the CholUAS7 as the best-suited composite diary score to assess disease activity, and therefore this score was used to determine changes in disease activity in response to treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>Statistical analyses were performed with GraphPad Prism Version 6 for Windows (2012; GraphPad Software, La Jolla, Calif).</s><s>The statistical significance of differences between patient groups was calculated by using Mann-Whitney U and x 2 tests.</s><s>Correlations were calculated with the Spearman rank test.</s><s>A P value of less than .05</s><s>was considered to indicate a significant difference.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional PCE results</head><p><s>At baseline, we observed a statistically significant correlation between time to wheal onset in PCE provocation and the CholUSI score (r s 5 20.39,</s><s>P 5 .04).</s><s>In line with previous observations, <ref type="bibr">E1</ref> we found no correlation between the change in core body temperature and the time to wheal onset during PCE provocation, the UASprovo score, the CholUSI score, or the PGA.</s><s>PCE threshold levels (ie, time to wheal onset, time to onset of sweating, and change in core body core temperature before wheal onset) were not reduced by high-dose sgAH treatment (Table <ref type="table" target="#tab_0">I</ref>).</s><s>sgAH treatment at 4-fold the standard dose improved provocation test results (ie, reduced the development of urticaria symptoms in response to PCE provocation), although not significantly (UASprovo, 213%; P 5 .08).</s><s>Interestingly, no improvement was seen in the UA-Sprovo wheal score (24%, P 5 .22),</s><s>whereas the UASprovo itch score decreased by 21% (P 5 .15).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional diary/disease activity results</head><p><s>The reduction in several calculated scores is described in Table <ref type="table" target="#tab_3">E3</ref>.</s><s>Notably, updosing of sgAHs improved the CholUAS7 components wheal and itch (Wheal7, 238% [P 5.01]; Pruritus7, 241% [P 5.002]), whereas the CholUAS7 elicitor component (ie, exposure to eliciting triggers) remained unchanged (Table <ref type="table" target="#tab_3">E3</ref>).</s></p><p><s>sgAH updosing for more than 7 days did not significantly improve disease activity compared with 7 days of treatment (CholUAS7 improvement: &gt;7 days of treatment; mean 6 SD: 14.2 6 5.4 days of treatment [n 5 11]: 8.5 6 12.9 points vs 7 days of treatment [n 5 17]: 6.6 6 7.8 points; P 5 .67).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sex differences in sgAH treatment</head><p><s>Interestingly, more women (53%) exhibited an improved Pruritusprovo score (&gt; _1-point improvement) compared with men (33%; P 5 .004,</s><s>x 2 test).</s><s>In contrast, 44% of the men improved in the Whealprovo score (&gt; _1-point improvement), but only 16% of the women did so (P &lt; .001,</s><s>x 2 test).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effect size of antihistamine updosing, as assessed by use of the CholUAS7</head><p><s>In our study the efficacy of sgAH updosing in patients with difficult-to-treat CholU was significant but overall moderate, with a reduction in disease activity defined by a CholUAS7 score of about 40%.</s><s>The difference was reported in comparison with 2 older studies using cetirizine updosing.</s><s>E8,E9 In one of these earlier studies, the mean reductions in single-symptom items (wheals, erythema, and itch) were calculated based on diary-derived data from selected days (ie, days when eliciting factors were present).</s><s>In contrast, our study included only patients who had previously failed standard sgAH treatment, and we assessed disease activity before and during high-dose sgAH treatment using the Chol-UAS7, which reflects the symptoms of a whole week.</s><s>In our study the CholUAS7 score showed good correlation with other outcome measures, such as the DLQI, the UASprovo score, and the time to onset of PCE provocation-induced symptoms, which corroborates the effect size determined by using this score.</s></p><p><s>In patients with CholU, high-dosed sgAHs affect itch more than wheals Of all single-item scores, the Pruritus7 score showed the most significant improvement in response to high-dose sgAHs.</s><s>Also, 36% of patients reported an improvement (&gt;50%) in their PCEinduced itch, whereas this was only true for 4% with regard to PCE-induced wheals.</s><s>Zuberbier et al, E8,E9 using 20 mg of cetirizine, also reported itch to show the most significant improvement of all outcomes assessed.</s><s>These findings provide evidence for what sgAH-treated patients with CholU often report in daily clinical practice: ''I still get wheals, but they don't itch so much anymore.''</s><s>The mechanisms of this differential response of itch and wheals to sgAH treatment remain unknown.</s><s>Critical histamine thresholds might be higher for wheal than for itch induction in patients with CholU, or mast cell mediators other than histamine might be more important for wheal formation than for pruritus development.</s><s>Interestingly, wheals and itch were affected differently by sgAH updosing in women and men, with better improvement of itch in women and better improvement of wheals in men.</s><s>To our knowledge, these sex-specific differences have not been reported before in patients with CholU.</s></p><p><s>Provocation testing is a valuable tool for assessing CholU activity but not suitable for detecting moderate changes of CholU activity in response to treatment</s></p><p><s>The good correlation of disease activity assessed by using the CholUAS7 and PCE provocation testing found in our study confirms that PCE is a valid and valuable instrument for the diagnostic workup of patients with CholU.</s><s>Provocation testing is recommended in patients with chronic inducible urticaria, such as CholU, to confirm the diagnosis and assess trigger thresholds.</s><s>PCE does both.</s></p><p><s>In contrast, PCE provocation testing did not detect moderate changes in disease activity in response to high-dose sgAH treatment.</s><s>In other words updosing of sgAH did not alter the time to onset of PCE-induced wheals.</s><s>This is different from other forms of inducible urticaria (eg, cold urticaria), where treatment responses to antihistamine treatment can be assessed by measuring changes in trigger thresholds (eg, critical temperature thresholds).</s><s><ref type="bibr">E10</ref> There are 2 likely explanations for this.</s><s>First, disease activity in our patients was rather high, their trigger thresholds were low (ie, not measurable in more than one third because of wheals at onset of PCE), and the effects of sgAH treatment were moderate.</s><s>Low trigger thresholds in patients with CholU might be less susceptible to treatment effects, especially suboptimal treatment effects, than higher thresholds.</s></p><p><s>In a previous case report we demonstrated that treatment can change PCE trigger thresholds (ie, increase the delay in the onset of PCE-induced wheals).</s><s><ref type="bibr">E11</ref> However, in this patient the treatment worked very well, with significantly reduced disease activity and markedly improved quality of life.</s></p><p><s>Second, PCE might have a lower sensitivity than diary-based activity scores, such as CholUAS7, for picking up moderate treatment effects, because in daily life the strength of triggers is usually lower than in PCE.</s><s>Antihistamines are likely to better protect against CholU symptoms induced by-mild-to moderate elicitors (daily life situation) compared with strong elicitors (PCE).</s><s>*CholUSI 5 sum score of (1) the frequency of CholU symptoms (less than once a month 5 0; once a month 5 1; more than once a month 5 2; once a week 5 3; more than once a week 5 4; daily 5 5; and more than once daily 5 6 points), (2) eliciting factors (1 point for each: physical exercise, hot bath, hot shower, emotional stress, hot food, sauna, and other), (3) duration of skin lesions (&lt;5 minutes 5 0; 5-10 minutes 5 1; 10-20 minutes 5 2; 20-30 minutes 5 3; 30-60 minutes 5 4; and &gt;1 hour 5 5 points), and (4) itch (none 5 0; mild 5 1; moderate 5 2; and severe 5 3 points).</s><s>Range is 0 to 21 (very mild 5 1-4 points; mild 5 5-9 points; moderate 5 10-15 points; and severe 5 &gt;16 points).</s><s>PGA score: range is 0 to 3 (none 5 0; mild 5 1; moderate 5 2; and severe 5 3).</s><s>*CholUSI 5 sum score of (1) the frequency of CholU symptoms (less than once a month 5 0; once a month 5 1; more than once a month 5 2; once a week 5 3; more than once a week 5 4; daily 5 5; and more than once daily 5 6 points), (2) eliciting factors (1 point for each: physical exercise, hot bath, hot shower, emotional stress, hot food, sauna, and other), (3) duration of skin lesions (&lt;5 minutes 5 0; 5-10 minutes 5 1; 10-20 minutes 5 2; 20-30 minutes 5 3; 30-60 minutes 5 4; and &gt;1 hour 5 5 points), and (4) itch (none 5 0; mild 5 1; moderate 5 2; and severe 5 3 points).</s><s>Range is 0 to 21 (very mild 5 1-4 points; mild 5 5-9 points; moderate 5 10-15 points; and severe 5 &gt;16 points).</s><s>PGA score: range is 0 to 3 (none 5 0, mild 5 1, moderate 5 2, and severe 5 3).</s><s>àDLQI: range is 0 to 30 (no impairment 5 0-1 points; mild impairment 5 2-5 points; moderate impairment 5 6-10 points; very large impairment 5 11-20 points; and extremely large impairment 5 21-30 points).</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIG 1 .</head><label>1</label><figDesc><div><p><s>FIG 1. Less than half of all patients with CholU treated with high-dose antihistamines experience complete protection.</s><s>Five categories of improvement are depicted, and proportions of patients in each category are shown.</s><s>Absolute numbers of patients are shown in parentheses.</s><s>A, Thirty-nine percent, 43%, and 46% of patients with CholU had 50% or greater improvement with high-dose antihistamines in the CholUAS7 score, the composite pruritus score 7 (CholPruritus7), and the composite wheal score 7 (CholWheal7), respectively.</s><s>B, Only 7% of patients with CholU had 50% or greater improvement in the UASprovo score.</s><s>Improvement was primarily seen in itch severity (36%) but not in wheal intensity (4%).</s><s>C, Thirty-nine percent of the patients with CholU reported a DLQI score reduction of 50% or greater.</s><s>CholUAS7 5 7-day sum of ([Whealday 1 Itchday] 3 Intensity of Elicitorday); range 5 0 to 168.</s><s>CholPruritus7 5 7-day sum of (Pruritusday 3 Intensity of Elicitorday); range 5 0 to 84.</s><s>CholWheal7 5 7-day sum of (Whealday 3 Intensity of Elicitorday); range 5 0 to 84.</s><s>UASprovo 5 Whealprovo 1 Itchprovo; range 5 0 to 6. Pruritusprovo: range 5 0 to 3. Whealprovo: range 5 0 to 3. DLQI: range 5 0-30 (no impairment 5 0-1 points; mild impairment 5 2-5 points; moderate impairment 5 6-10 points; very large impairment 5 11-20 points; and extremely large impairment 5 21-30 points).</s></p></div></figDesc><graphic coords="2,69.39,421.91,442.51,130.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>); range 5 0 to 168.</s><s>Elicitor7 5 7-day sum of intensity of Elicitorday [no exposure to elicitors 5 4, exposure to mild elicitor 5 3, exposure to moderate elicitor 5 2, and exposure to strong elicitor 5 1 point]; range 5 0 to 28. àDLQI; range 5 0 to 30 (no impairment 5 0-1 points; mild impairment 5 2-5 points; moderate impairment 5 6-10 points; very large impairment 5 11-20 points; and extremely large impairment 5 21-30 point).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>FIG E1 .</head><label>E1</label><figDesc><div><p><s>FIG E1.</s><s>Study flow chart.</s><s>UASprovo, Urticaria activity score after PCE provocation testing.</s></p></div></figDesc><graphic coords="7,44.84,65.59,239.02,222.46" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>TABLE I .</head><label>I</label><figDesc><div><p><s>High-dose antihistamine treatment reduces disease activity in patients with CholU refractory to standard doses (n 5 28)</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>End of high-dose sgAH</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Baseline, mean 6 SD</cell><cell>treatment, mean 6 SD</cell><cell></cell><cell></cell></row><row><cell></cell><cell>(median; [range])</cell><cell>(median; range)</cell><cell>Improvement (%)</cell><cell>P value</cell></row><row><cell cols="2">Diary-documented disease activity and quality of life impairment</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Disease activity</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CholUAS7*</cell><cell>43.6 6 28.5 (37.0; 9 to 114)</cell><cell>25.9 6 15.4 (24.0; 0 to 68)</cell><cell>40.6</cell><cell>.01</cell></row><row><cell>Wheal7</cell><cell>8.4 6 5.8 (9.0; 0 to 21)</cell><cell>5.2 6 5.7 (4.0; 0 to 21)</cell><cell>38.1</cell><cell>.01</cell></row><row><cell>Pruritus7</cell><cell>10.2 6 5.1 (9.0; 2 to 21)</cell><cell>6.0 6 4.6 (5.5; 0 to 20)</cell><cell>41.2</cell><cell>.002</cell></row><row><cell>Intensity of elicitors</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Elicitor7</cell><cell>20.1 6 4.8 (21.0; 7 to 28)</cell><cell>20.8 6 4.3 (21.0; 7 to 28)</cell><cell>23.5</cell><cell>.44</cell></row><row><cell>Quality of life</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>DLQI scoreà</cell><cell>9.7 6 6.3 (8.5; 1 to 26)</cell><cell>7.6 6 7.2 (5.5; 0 to 27)</cell><cell>21.6</cell><cell>.09</cell></row><row><cell>PCE provocation test results</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>PCE-induced CholU activity</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>UASprovo score</cell><cell>4.7 6 1.1 (5.0; 2 to 6)</cell><cell>4.1 6 1.2 (4.0; 2 to 6)</cell><cell>12.8</cell><cell>.08</cell></row><row><cell>Whealprovo score</cell><cell>2.8 6 0.5 (3.0; 1 to 3)</cell><cell>2.7 6 0.6 (3.0; 1 to 3)</cell><cell>3.6</cell><cell>.22</cell></row><row><cell>Pruritusprovo score</cell><cell>1.9 6 0.9 (2.0; 1 to 3)</cell><cell>1.5 6 1.0 (1.0; 0 to 3)</cell><cell>21.1</cell><cell>.15</cell></row><row><cell>PCE-induced wheal onset</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Time to wheal onset (min)</cell><cell>11.3 6 10.0 (12.5; 0 to 28)</cell><cell>12.2 6 10.4 (13.0; 0 to 29)</cell><cell>7.4</cell><cell>.78</cell></row><row><cell>Increase in HR (beats/min) at wheal onset</cell><cell>33.3 6 32.7 (26.5; 216 to 109)</cell><cell>35.1 6 31.6 (38.5; 0 to 99)</cell><cell>5.1</cell><cell>.53</cell></row><row><cell>Increase in BCT at wheal onset (8C)</cell><cell>0.4 6 0.7 (0.1; 20.3 to 2.7)</cell><cell>0.6 6 1.0 (0.2; 20.5 to 3.3)</cell><cell>33.3</cell><cell>.48</cell></row><row><cell>PCE-induced onset of sweating</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Time to onset of sweating (min)</cell><cell>14.9 6 6.2 (15.5; 0 to 26)</cell><cell>13.3 6 7.0 (13.5; 0 to 28)</cell><cell>212.0</cell><cell>.63</cell></row><row><cell>Increase in HR at onset of sweating (beats/min)</cell><cell>41.9 6 28.5 (44.0; 21 to 99)</cell><cell>32.9 6 30.4 (37.5; 0 to 91)</cell><cell>227.4</cell><cell>.28</cell></row><row><cell>Increase in BCT at onset of sweating (8C)</cell><cell>0.4 6 0.5 (0.3; 20.2 to 1.7)</cell><cell>0.6 6 0.8 (0.3; 20.5 to 3.4)</cell><cell>33.3</cell><cell>.64</cell></row></table><note><p><s>Values in boldface indicate statistical significance.</s><s>BCT, Body core temperature; HR, heart rate.</s><s>*CholUAS7 5 7-day sum of ([Whealday 1 Itchday] 3 Intensity of Elicitorday</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE E1 .</head><label>E1</label><figDesc><div><p><s>Detailed score description</s></p></div></figDesc><table><row><cell>Score: name</cell><cell>Calculation</cell><cell>Maximum points</cell></row><row><cell>Weekly UAS: UAS7</cell><cell>7-d Sum of (Whealday 1 Itchday)</cell><cell>42</cell></row><row><cell>Weekly wheal score: Wheal7</cell><cell>7-d Sum of Whealday</cell><cell>21</cell></row><row><cell>Weekly pruritus score: Pruritus7</cell><cell>7-d Sum of Itchday</cell><cell>21</cell></row><row><cell>Cholinergic UAS7: CholUAS7</cell><cell>7-d Sum of ([Whealday 1 Itchday] 3 Intensity of elicitorday)</cell><cell>168</cell></row><row><cell>Cholinergic wheal7: CholWheal7</cell><cell>7-d Sum of (Whealday 3 Intensity of elicitorday)</cell><cell>84</cell></row><row><cell>Cholinergic pruritus7: CholPruritus7</cell><cell>7-day Sum of (Itchday 3 Intensity of elicitorday)</cell><cell>84</cell></row><row><cell>Alternative cholinergic UAS7: aCholUAS7</cell><cell>7-d Sum of (Whealday 1 Itchday 1 Intensity of elicitorday)</cell><cell>70</cell></row><row><cell>Alternative cholinergic wheal7: aCholWheal7</cell><cell>7-d Sum of (Whealday 1 Intensity of elicitorday)</cell><cell>49</cell></row><row><cell>Alternative cholinergic pruritus7: aCholPruritus7</cell><cell>7-d Sum of (Itchday 1 Intensity of elicitorday)</cell><cell>49</cell></row><row><cell>Weekly intensity of elicitors: Elicitor7</cell><cell>7-d Sum of Intensity of elicitorday</cell><cell>28</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>TABLE E2 .</head><label>E2</label><figDesc><div><p><s>Correlations of diary scores with different anchors (n 5 28)Values in boldface indicate statistical significance (P &lt; .05,</s><s>r s Spearman correlation coefficient).</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Time to onset of</cell></row><row><cell></cell><cell>UASprovo score</cell><cell>Whealprovo score</cell><cell>Pruritusprovo score</cell><cell>DLQI score</cell><cell>wheals (in PCE)</cell></row><row><cell></cell><cell>Correlation</cell><cell>Correlation</cell><cell>Correlation</cell><cell>Correlation</cell><cell>Correlation</cell></row><row><cell></cell><cell>coefficient (P value)</cell><cell>coefficient (P value)</cell><cell>coefficient (P value)</cell><cell>coefficient (P value)</cell><cell>coefficient (P value)</cell></row><row><cell cols="2">Disease activity (diary-based scores)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>UAS7 score</cell><cell>0.30 (.12)</cell><cell>0.14 (.48)</cell><cell>0.30 (.12)</cell><cell>0.31 (.10)</cell><cell>20.39 (.04)</cell></row><row><cell>Wheal7 score</cell><cell>0.15 (.44)</cell><cell>0.20 (.30)</cell><cell>0.12 (.55)</cell><cell>0.18 (.35)</cell><cell>20.29 (.13)</cell></row><row><cell>Pruritus7 score</cell><cell>0.49 (.008)</cell><cell>0.14 (.48)</cell><cell>0.50 (.007)</cell><cell>0.36 (.06)</cell><cell>20.40 (.03)</cell></row><row><cell>CholUAS7 score</cell><cell>0.36 (.06)</cell><cell>0.05 (.82)</cell><cell>0.39 (.04)</cell><cell>0.30 (.12)</cell><cell>20.42 (.03)</cell></row><row><cell>CholWheal7 score</cell><cell>0.16 (.40)</cell><cell>0.08 (.68)</cell><cell>0.17 (.38)</cell><cell>0.16 (.43)</cell><cell>20.35 (.07)</cell></row><row><cell>CholPruritus7 score</cell><cell>0.48 (.01)</cell><cell>0.009 (.97)</cell><cell>0.53 (.004)</cell><cell>0.32 (.09)</cell><cell>20.40 (.03)</cell></row><row><cell>aCholUAS7 score</cell><cell>0.28 (.14)</cell><cell>0.09 (.64)</cell><cell>0.29 (.13)</cell><cell>0.30 (.13)</cell><cell>20.38 (.05)</cell></row><row><cell>aWheal7 score</cell><cell>0.004 (.98)</cell><cell>0.05 (.80)</cell><cell>0.01 (.95)</cell><cell>20.04 (.82)</cell><cell>20.19 (.33)</cell></row><row><cell>aPruritus7 score</cell><cell>0.25 (.21)</cell><cell>20.12 (.53)</cell><cell>0.32 (.10)</cell><cell>0.13 (.50)</cell><cell>20.33 (.08)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>TABLE E3 .</head><label>E3</label><figDesc><div><p><s>High-dose antihistamine treatment reduces disease activity in patients with CholU refractory to standard doses (n 5 28)</s></p></div></figDesc><table><row><cell>Baseline, mean 6 SD</cell><cell>End of treatment, mean 6 SD</cell><cell></cell><cell></cell></row><row><cell>(median; range)</cell><cell>(median; range)</cell><cell>Improvement (%)</cell><cell>P value</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>TABLE E4 .</head><label>E4</label><figDesc><div><p><s>Patients' characteristics</s></p></div></figDesc><table><row><cell>Patients with CholU (n 5 28)</cell><cell>Mean 6 SD (median; range)</cell></row><row><cell>Age (y)</cell><cell>34.0 6 20.0 (29.5; 19-76)</cell></row><row><cell>BMI (kg/m 2 )</cell><cell>24.2 6 5.2 (24.0; 19.4-37.2)</cell></row><row><cell>Duration of disease (y)</cell><cell>7.6 6 8.5 (5.0; 1-43)</cell></row><row><cell>Duration of wheals (h)</cell><cell>1.5 6 2.3 (1.0; 0.25-12)</cell></row><row><cell>Severity of disease</cell><cell></cell></row><row><cell>CholUSI*</cell><cell>14.6 6 2.4 (15.0; 9-18)</cell></row><row><cell>PGA score</cell><cell>2.3 6 0.8 (2.5; 1-3)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>TABLE E5 .</head><label>E5</label><figDesc><div><p><s>Comparison of responders (CholUAS7 &gt; _50% improvement) and nonresponders (CholUAS7 &lt;50% improvement [n 5 28]) Values in boldface indicate statistical significance (P &lt; .05,</s><s>x 2 test).</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>CholUAS7</cell><cell></cell></row><row><cell></cell><cell>Responders (n 5 11)</cell><cell>Nonresponders (n 5 17)</cell><cell>P value</cell></row><row><cell>Cetirizine, 40 mg/d</cell><cell>4</cell><cell>2</cell><cell>.22</cell></row><row><cell>Rupatadine, 40 mg/d</cell><cell>5</cell><cell>10</cell><cell>.70</cell></row><row><cell>Loratadine, 40 mg/d, or</cell><cell>0</cell><cell>3</cell><cell>.18</cell></row><row><cell>desolatadine, 20 mg/d</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Ebastine, 40 mg/d</cell><cell>2</cell><cell>1</cell><cell>.36</cell></row><row><cell>Fexofenadine, 480 mg/d</cell><cell>0</cell><cell>1</cell><cell>.43</cell></row><row><cell>Age (y), mean 6 SD</cell><cell>38.1 6 25.0</cell><cell>31.1 6 4.7</cell><cell>.35</cell></row><row><cell>Sex (female/male)</cell><cell>9/2</cell><cell>10/7</cell><cell>.20</cell></row><row><cell>Duration of disease (y),</cell><cell>5.6 6 4.9</cell><cell>9.9 6 10.1</cell><cell>.55</cell></row><row><cell>mean 6 SD</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CholUSI,* mean 6 SD</cell><cell>13.9 6 3.5</cell><cell>15.1 6 2.2</cell><cell>.29</cell></row><row><cell>PGA score, mean 6 SD</cell><cell>1.8 6 1.2</cell><cell>2.5 6 0.0</cell><cell>.03</cell></row><row><cell>DLQI,à mean 6 SD</cell><cell>9.6 6 6.6</cell><cell>9.8 6 6.3</cell><cell>.98</cell></row><row><cell>Erlanger atopy score,</cell><cell>11.5 6 4.2</cell><cell>12.7 6 2.8</cell><cell>.38</cell></row><row><cell>mean 6 SD</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOL VOLUME 138, NUMBER 5 LETTERS TO THE EDITOR 1483</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOL VOLUME 138, NUMBER 5 LETTERS TO THE EDITOR 1485.e2</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOL VOLUME 138, NUMBER 5</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOLNOVEMBER 2016</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0" />
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Haematopoietic and immune defects associated with GATA2 mutation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Collin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dickinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bigley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="173" to="187" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The evolution of cellular deficiency in GATA2 mutation</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Dickinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Milne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jardine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Swierczek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mcgovern</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="863" to="874" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">GATA-2 mediated regulation of normal hematopoietic stem/progenitor cell function, myelodysplasia and myeloid leukemia</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Rodrigues</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Tipping</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">K</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Enver</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Biochem Cell B</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="457" to="460" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">GATA2 deficiency</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Mcreynolds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Holland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="104" to="109" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Pasquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bellanne-Chantelot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tavitian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Prade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Beaupain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Larochelle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="822" to="829" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Spinner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Shaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Zerbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Calvo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="809" to="821" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Mir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Kochuparambil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Abraham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Howard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Hsu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Med</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="490" to="499" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency</title>
		<author>
			<persName><forename type="first">J</forename><surname>Grossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cuellar-Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gea-Banacloche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zerbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Calvo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hughes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1940" to="1948" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" type="main">Available online</title>
		<idno type="DOI">10.1016/j.jaci.2016.06.004</idno>
		<ptr target="http://dx.doi.org/10.1016/j.jaci.2016.06.004" />
		<imprint>
			<date type="published" when="2016-07-29">July 29. 2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Prevalence of cholinergic urticaria in young adults</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Althaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chantraine-Hess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Czarnetzki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="978" to="981" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">New concepts of hive formation in cholinergic urticaria</title>
		<author>
			<persName><forename type="first">T</forename><surname>Horikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fukunaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nishigori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Allergy Asthma Rep</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="273" to="279" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Physical urticarias and cholinergic urticaria</title>
		<author>
			<persName><forename type="first">M</forename><surname>Abajian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Schoepke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Allergy Clin North Am</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="73" to="88" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Cholinergic urticaria: pathogenesis-based categorization and its treatment options</title>
		<author>
			<persName><forename type="first">S</forename><surname>Nakamizo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Egawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Miyachi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kabashima</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="114" to="116" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Brzoza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Canonica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="868" to="887" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Efficacy of cetirizine in cholinergic urticaria</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Burtin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Rihoux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Czarnetzki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="147" to="149" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Double-blind crossover study of high-dose cetirizine in cholinergic urticaria</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Munzberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Haustein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Trippas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Burtin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Mariz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatology</title>
		<imprint>
			<biblScope unit="volume">193</biblScope>
			<biblScope unit="page" from="324" to="327" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria</title>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Salow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ardelean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dermatol Sci</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="88" to="93" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H(1)-antihistamine dose escalation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pisarevskaja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Staubach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page" from="1095" to="1099" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Successful treatment of cholinergic urticaria with methantheliniumbromide</title>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wosny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dermatol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="422" to="424" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Available</forename><surname>Online</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jaci.2016.05.026</idno>
		<ptr target="http://dx.doi.org/10.1016/j.jaci.2016.05.026" />
		<imprint>
			<date type="published" when="2016-06-29">June 29. 2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria</title>
		<author>
			<persName><surname>References E1</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Salow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ardelean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dermatol Sci</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="88" to="93" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Brzoza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Canonica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="868" to="887" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Khan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="210" to="216" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Autonomic neuropathy in the skin: a histological study of the sympathetic nerve fibres in diabetic anhidrosis</title>
		<author>
			<persName><forename type="first">I</forename><surname>Faerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Faccio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Calb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Razumny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Franco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dominguez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="96" to="99" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Accuracy and precision of a novel non-invasive core thermometer</title>
		<author>
			<persName><forename type="first">O</forename><surname>Kimberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Thell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schuh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Sessler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kurz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Anaesth</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="226" to="231" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Determining core body temperature via heat flux-a new promising approach</title>
		<author>
			<persName><forename type="first">O</forename><surname>Opatz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Gunga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Resuscitation</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="1588" to="1589" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>author reply 9</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">The Double Sensor-A non-invasive device to continuously monitor core temperature in humans on earth and in space</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Gunga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Steinach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Schlabs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Koralewski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Respir Physiol Neurobiol</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S63" to="68" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Efficacy of cetirizine in cholinergic urticaria</title>
		<author>
			<persName><forename type="first">E8</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Burtin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rihoux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Czarnetzki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="147" to="149" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Double-blind crossover study of high-dose cetirizine in cholinergic urticaria</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Munzberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Haustein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Trippas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Burtin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Mariz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatology</title>
		<imprint>
			<biblScope unit="volume">193</biblScope>
			<biblScope unit="page" from="324" to="327" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H(1)-antihistamine dose escalation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pisarevskaja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Staubach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page" from="1095" to="1099" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Successful treatment of cholinergic urticaria with methantheliniumbromide</title>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wosny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dermatol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="422" to="424" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title level="m">Disease activity (diary-based scores) UAS7 day sum of</title>
				<imprint/>
	</monogr>
	<note>Whealday 1 Itchday] 1 Intensity of elicitorday); range 5 0 to 70. kaCholWheal7 5 7-day sum of (Whealday 1 Intensity of elicitorday); range 5 0 to 49. {aCholPruritus7 5 7-day sum of (Pruritusday 1 Intensity of elicitorday); range 5 0 to 49</note>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title level="m">#Elicitor7 5 7-day sum of Intensity of elicitorday</title>
				<imprint/>
	</monogr>
	<note>no exposure to elicitors 5 4; exposure to mild elicitor 5 3; exposure to moderate elicitor 5 2; and exposure to strong elicitor 5 1 point); range 5 0 to 28</note>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title level="m" type="main">points; mild impairment 5 2-5 points; moderate impairment 5 6-10 points</title>
		<author>
			<persName><forename type="first">**</forename><surname>Dlqi</surname></persName>
		</author>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="0" to="1" />
		</imprint>
	</monogr>
	<note>range 5 0 to. very large impairment 5 11-20 points; and extremely large impairment 5 21-30 points</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
